Previous phase 2b and 3 multicenter RCTs on anticoagulant therapy in sepsis or septic shock, including tissue factor pathway inhibitor (TFPI) (OPTIMIST study) in 2003 (28), APC in 2012 (29), AT in 2013 (30) and rhTM in 2013 (31), explored the effects of anticoagulants in patients with sepsis or severe sepsis. The gene discussed is TFPI; the disease is Sepsis.